Press Releases Qiagen N.V.

Equities

QGEN

NL0015002SN0

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:03 11/05/2026 BST			5-day change	1st Jan Change
32.63 ^USD	-1.24%		-3.92%	-31.07%

05-08	QIAGEN NV : Gets a Neutral rating from Barclays	ZD
05-07	Qiagen N.V. - Special Call

Press Releases

05-11	Qiagen N : Full Q1 2026 Results Investor Introduction	PU
05-07	Qiagen N : BofA Securities 2026 Healthcare Conference Investor introduction	PU
05-07	QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing	BU
05-07	Full Q1 2026 Results Presentation: Wednesday, May 6, 2026	PU
05-06	Qiagen: Q1 Earnings Snapshot	AQ
05-06	QIAGEN Reports Full Results for Q1 2026	BU
05-06	Qiagen Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Qiagen N.V. (QGEN)	PR
04-30	Qiagen N : 2025 Annual Report 2025 IFRS Annual Report	PU
04-28	Preliminary Q1 2026 Results Conference Call Presentation: Tuesday, April 28, 2026	PU
04-28	Qiagen N : hoc Announcement according to Art. 17 Market Abuse Regulation	PU
04-27	Preliminary Q1 2026 Results Webcast Dial-in Details: Tuesday, April 28, 2026	PU
04-27	QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook	BU
04-27	QIAGEN N.V.: QIAGEN announces preliminary Q1 2026 results that achieved adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook by reducing expected net sales growth and adj. EPS	EQ
04-16	QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026	BU
04-15	Qiagen N : Sustainability Report (qiagen uk gender pay 2025 website v3)	PU
04-14	QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel	BU
04-01	Qiagen N : Sustainability Report (QIAGEN UK GENDER PAY 2025 website v3)	PU
03-20	Qiagen Announces Form 20-F Annual Report Filing for 2025 Results	BU
03-20	Qiagen N : Annual Report for Fiscal Year Ending December 31, 2025 (Form 20-F)	PU
03-19	QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention	BU
03-12	Qiagen N : Sustainability Report (supplier code of conduct 2026)	PU
03-11	Qiagen N : BlackRock Inc. - Qiagen N.V. - VENLO	PU
03-10	QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System	BU
03-04	Qiagen N : Barclays Global Healthcare Conference Investor Introduction	PU
02-23	Qiagen N : Sustainability Report (esg faqs final 0226)	PU